Anti-Tigit drug of Roche fails stage study
Roche's Genentech had disappointing news to share this week regarding its lung cancer hopeful.
Roche Genentech | 26/04/2022 | By Sudeep Soparkar | 591
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy